Abubakr Bajwa, MD
Pulmonary Disease · Jacksonville, FLNPI 1467442392
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $268,404 of the $413,573 with a category attached, or 64.9%. 26 manufacturers reported payments, led by United Therapeutics Corporation at 35.4% of the total. Reporting peaked in 2021 at $114,884 and has fallen 95.5% since, to $5,184 in 2025. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 487 payments — averaging $849.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$147K
- Boehringer Ingelheim$109K
- Intuitive Surgical$65K
- Actelion Pharmaceuticals US, Inc.$51K
- Insmed, Inc.$20K
- Bayer$10K
- plus $12K from 20 others
Across 163 payments — averaging $6185.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$683K
- AstraZeneca$146K
- Janssen Research & Development, LLC$81K
- Actelion Pharmaceuticals, Ltd$52K
- Insmed, Inc.$23K
- Bayer$19K
- plus $4K from 1 others
What the payments were for
- Consulting fees$49,44512%
- Speaking & faculty fees$268,40465%
- Travel & lodging$30,2817%
- Food & beverage$17,5354%
- Education$47,77112%
- Gifts$1370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 151 | $146,607 |
| Boehringer Ingelheim | 80 | $108,889 |
| Intuitive Surgical | 76 | $65,207 |
| Actelion Pharmaceuticals US, Inc. | 65 | $50,963 |
| Insmed, Inc. | 21 | $19,579 |
| Bayer | 11 | $10,211 |
| AstraZeneca | 26 | $8,548 |
| Pulmonx Corporation | 12 | $1,915 |
| Merck | 8 | $426 |
| Inspire Medical Systems, Inc. | 7 | $369 |
| GSK | 7 | $221 |
| Genentech USA, Inc. | 5 | $161 |
| Vapotherm Inc | 1 | $123 |
| Ambu Inc. | 1 | $80 |
| Mylan Specialty L.p. | 2 | $39 |
| Mallinckrodt Enterprises LLC | 2 | $37 |
| Gilead | 2 | $29 |
| Sunovion Pharmaceuticals Inc. | 2 | $28 |
| Johnson & Johnson | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $20 |
| Grifols USA, LLC | 1 | $19 |
| Sanofi | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| AbbVie | 1 | $14 |
| Novartis | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYVASO$72,334
- OFEV$63,317
- Da Vinci Surgical System$59,929
- UPTRAVI$43,620
- OPSUMIT$31,699
- ORENITRAM$23,596
- REMODULIN$21,018
- Arikayce$15,149
- NONE$10,237
- Adempas$10,099
- FASENRA$8,072
- DA VINCI SP$4,150
- Pulmonx Endobronchial Valve EBV$1,073
- CHARTIS CATHETER$294
- ZEPHYR DELIVERY CATHETER$294
- ZEPHYR ENDOBRONCHIAL VALVE$294
- PULMONX CHARTIS TABLET CONSOLE$294
- WINREVAIR$242
- Inspire$231
- Esbriet$126
How this compares
$413,573 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 60 | $767,466 |
| Tyvaso DpiTreprostinil | 22 | $523,952 |
| Orenitram ErTreprostinil Diolamine | 14 | $434,565 |
| UptraviSelexipag | 15 | $273,187 |
| OpsumitMacitentan | 12 | $150,849 |
| Pirfenidone | 13 | $69,384 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $54,333 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $9,425 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $4,554 |
| Wixela InhubFluticasone Propion/Salmeterol | 16 | $1,135 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 33 | $777 |
| Ventolin HfaAlbuterol Sulfate | 11 | $593 |
| Azithromycin | 39 | $372 |
| Montelukast Sodium | 29 | $188 |
| Gabapentin | 16 | $122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Combivent Respimat | $108,889 | $776,89177 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $50,963 | $424,03627 claims |
| GSKTrelegy Ellipta | $221 | $54,33375 claims |
| AstraZenecaSymbicort | $8,548 | $4,55418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Jacksonville
- Jennifer FultonJacksonville$665K
- Jose Soto SotoJacksonville$504K
- Jorge MalleaJacksonville$457K
- Bryan HustaJacksonville$283K
- Sebastian Fernandez-BussyJacksonville$257K
- Peter NassarJacksonville$141K
- Charles BurgerJacksonville$124K
- Daniel WyzanJacksonville$100K
- David Abia TrujilloJacksonville$68K
- Franck RahaghiWeston$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.